Cogent Biosciences (COGT) vs Genmab A/S (GMAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cogent Biosciences (COGT) has outperformed Genmab A/S (GMAB) over the past year, gaining 95.2% versus a gain of 12.3%. Over five years, COGT leads with a +226.2% price change compared with -17.5% for GMAB. Genmab A/S is the larger company by market cap ($22.17 billion vs $5.22 billion), about 4.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COGT | GMAB |
|---|---|---|
| Share price | $30.08 | $36.05 |
| Market cap | $5.22B | $22.17B |
| 1-day change | -0.20% | -1.64% |
| YTD return | -15.15% | +18.99% |
| 1-year return | +95.21% | +12.29% |
| 5-year return | +226.19% | -17.51% |
| P/E ratio (TTM) | — | 28.39 |
| Forward P/E | — | 23.64 |
| EPS (TTM) | $-2.16 | $1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $3.72B |
| Revenue growth (YoY) | — | +19.19% |
| Net income (latest FY) | $-328.94M | $963.00M |
| Gross margin | — | 93.60% |
| Operating margin | — | 28.63% |
| Net margin | — | 25.89% |
| 52-week high | $43.73 | $40.17 |
| 52-week low | $13.78 | $23.62 |
| Distance from 52-week high | -31.21% | -10.26% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +85.57% | +19.89% |
| Average volume | 1.90M | 2.80M |
| Shares outstanding | 173.52M | 614.90M |
| Employees | 258 | 3,119 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Genmab A/S is about 4.2 times larger than Cogent Biosciences by market value ($22.17B vs $5.22B).
- COGT has outperformed GMAB by 82.9 percentage points over the past year.
About Cogent Biosciences
COGT stock →Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
About Genmab A/S
GMAB stock →Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,119 employees
COGT vs GMAB FAQ
Which is bigger, Cogent Biosciences or Genmab A/S?
Genmab A/S (GMAB) is larger, with a market capitalization of $22.17B compared with $5.22B for Cogent Biosciences (COGT).
Which stock has performed better over the past year, COGT or GMAB?
COGT returned +95.21% over the past 12 months, compared with +12.29% for GMAB (price return, excluding dividends). Past performance does not predict future results.
Are Cogent Biosciences and Genmab A/S in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.